BLIS K12 Receives “No Objection” GRAS Letter From FDA

635914720924384696taste.jpg

19 Feb 2016 --- Oral-health probiotic BLIS K12 has received a “Letter of No Objection” from the US Food and Drink Administration (FDA) for its self-affirmed notification of Generally Recognized As Safe (GRAS) status.

The patented probiotic strain of Streptococcus salivarius, BLIS K12, has been studied for benefits to ear and throat health in children and adults, including reducing incidence of halitosis and Streptococal pharyngitis.
 
BLIS K12 developer Blis Technologies (Dunedin, New Zealand) and North America distributor Stratum Nutrition (Saint Charles, MO) celebrated the “No Objection” GRAS status as key to opening more markets for the probiotic:
 
“It adds a new level of credibility for BLIS K12 and puts the conversations with larger consumer food and beverage companies in the US on a stronger footing,” said Peter Fennessy, board chairman, Blis Technologies.
 
“Many of those companies are, quite rightly, risk averse. Therefore, having the non-objection notification from the FDA offers an additional level of confidence and makes it clearer where BLIS K12 fits within the category,” Fennessy added.
 
Jeremy Moore, managing director of Stratum Nutrition, added, “Very few ingredients in this space go to this level, so it is a definite feather in the cap for Blis.”
 
Through the GRAS program, companies may submit their determination, supported by research and expert review, that a specific ingredient is Generally Recognized As Safe. The Letter of No Objection means that the FDA has reviewed the data and has no questions regarding the notice submitted.

Related Articles

Nutrition & Health News

Clear definition and regulations needed to tap into nutraceuticals’ potential: review

13 Feb 2018 --- Nutraceuticals with health benefits substantiated by clinical data can be powerful tools to prevent and treat medical conditions, especially in individuals who may not yet be eligible for conventional pharmaceutical drugs. However, there is a clear need for clear regulations to ensure their safety. This is according to a review published in the British Journal of Clinical Pharmacology, which further proposes a clear definition for this type of product. 

Nutrition & Health News

Immunity boosters (Part 2): Not diplomatic about immunity – Innovation, new ingredients and R&D

12 Feb 2018 --- Immune health continues to drive trends in the nutrition industry. Today, in the second part of a special report, NutritionInsight continues its in-depth look at the latest ideas in the industry in the immune health space.

Nutrition & Health News

Probi’s largest clinical trial confirms the immune enhancing impact of Defendum probiotic

07 Feb 2018 --- Probi's largest clinical trial ever, focused on probiotic immune health, has confirmed a strong clinical immune enhancing effect of Probi Defendum. According to the company, the study proves that Probi Defendum helps protect against recurrent colds and sheds some light on the mechanism of action behind the effect.

Nutrition & Health News

Infant nutrition market becomes a bit more wholesome with gut-friendly organic yogurt launch

01 Feb 2018 --- Premium organic baby food brand Happy Family has launched what it says is the first-ever organic yogurt line with no added sweeteners for babies and toddlers. Designed for infants starting at six months and up to three years old, the Happy Baby and Happy Tot Whole Milk Yogurt line is made with whole milk, vitamin D and probiotics. 

Nutrition & Health News

The US Council for Responsible Nutrition welcomes eight new companies as members

30 Jan 2018 --- The Council for Responsible Nutrition (CRN), a US trade association for the dietary supplement and functional food industry, has welcomed eight new companies to its membership ranks.

More Articles
URL : http://www.nutritioninsight.com:80/news/blis-k12-receives-no-objection-gras-letter-from-fda.html